Korea Investment CORP Boosts Stock Position in Boston Scientific Corporation $BSX

Key Points

• Korea Investment CORP increased its stake in Boston Scientific Corporation by 18.1% during the first quarter, acquiring an additional 245,832 shares, bringing total ownership to approximately $161.6 million.
• Boston Scientific's recent earnings report showed a 22.8% year-over-year increase in revenue to $5.06 billion and an EPS of $0.75, surpassing analysts' expectations.
• Equity analysts demonstrate strong bullish sentiment towards Boston Scientific, with 22 "buy" ratings and a target price averaging $117.50.

Korea Investment CORP increased its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 18.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,602,112 shares of the medical equipment provider's stock after buying an additional 245,832 shares during the quarter. Korea Investment CORP owned about 0.11% of Boston Scientific worth $161,621,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Brooklyn Investment Group boosted its position in Boston Scientific by 11.7% in the first quarter. Brooklyn Investment Group now owns 12,971 shares of the medical equipment provider's stock valued at $1,309,000 after buying an additional 1,358 shares during the last quarter. Corient IA LLC acquired a new stake in Boston Scientific in the 1st quarter worth about $706,000. Raymond James Financial Inc. raised its stake in Boston Scientific by 1.9% in the 1st quarter. Raymond James Financial Inc. now owns 2,177,337 shares of the medical equipment provider's stock valued at $219,650,000 after purchasing an additional 41,422 shares during the last quarter. Boston Family Office LLC lifted its stake in shares of Boston Scientific by 32.3% in the first quarter. Boston Family Office LLC now owns 11,499 shares of the medical equipment provider's stock worth $1,160,000 after buying an additional 2,805 shares in the last quarter. Finally, Ethic Inc. boosted its holdings in shares of Boston Scientific by 11.1% during the 1st quarter. Ethic Inc. now owns 268,848 shares of the medical equipment provider's stock worth $27,218,000 after purchasing an additional 26,919 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Boston Scientific news, Director Yoshiaki Fujimori sold 2,901 shares of Boston Scientific stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total transaction of $310,377.99. Following the completion of the transaction, the director owned 2,081 shares in the company, valued at approximately $222,646.19. The trade was a 58.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the company's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the sale, the executive vice president directly owned 23,600 shares in the company, valued at $2,469,268. This trade represents a 42.32% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 345,029 shares of company stock valued at $35,976,603 in the last 90 days. Insiders own 0.50% of the company's stock.

Boston Scientific Stock Performance

Shares of BSX stock traded up $0.7850 during trading hours on Friday, reaching $105.9950. 8,236,724 shares of the company's stock were exchanged, compared to its average volume of 7,561,299. The company has a market cap of $157.06 billion, a P/E ratio of 63.09, a price-to-earnings-growth ratio of 2.55 and a beta of 0.66. The company's 50 day moving average is $103.97 and its two-hundred day moving average is $102.14. Boston Scientific Corporation has a 1 year low of $78.53 and a 1 year high of $108.94. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The company's revenue for the quarter was up 22.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities research analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Citigroup restated a "buy" rating and set a $125.00 price objective (up from $119.00) on shares of Boston Scientific in a research report on Thursday, May 22nd. Evercore ISI upped their target price on shares of Boston Scientific from $110.00 to $112.00 and gave the stock an "outperform" rating in a research note on Thursday, April 24th. Wells Fargo & Company boosted their price objective on Boston Scientific from $118.00 to $124.00 and gave the stock an "overweight" rating in a research report on Thursday, July 24th. Oppenheimer upped their price objective on Boston Scientific from $110.00 to $118.00 and gave the stock a "market perform" rating in a research report on Thursday, July 24th. Finally, Leerink Partnrs upgraded shares of Boston Scientific to a "strong-buy" rating in a research note on Monday, June 16th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $117.50.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.